<DOC>
	<DOCNO>NCT00848055</DOCNO>
	<brief_summary>The general aim trial determine safety , tolerability pharmacologic profile single escalate dos AbGn-168 administer subcutaneously intravenously patient chronic plaque psoriasis</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Doses AbGn-168 Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Patients chronic plaque psoriasis cover least 3 % body surface area . Female subject must postmenopausal surgically sterilize . Exclusion criterion : Recent use biologic agent , oral psoriasis medication phototherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>